Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unprecedented selectivity for homologous lectin targets, differential targeting of the viral receptors L-SIGN and DC-SIGN

  • Delaunay, Clara
  • Pollastri, Sara
  • Thepaut, Michel
  • Cavazzoli, Gianluca
  • Belvisi, Laura
  • Bouchikri, Clementine
  • Labiod, Nuria
  • Lasala, Fatima
  • Gimeno, Ana
  • Franconetti, Antonio|||0000-0002-7972-8795
  • Jiménez Barbero, Jesús|||0000-0001-5421-8513
  • Arda, Ana
  • Delgado, Rafael
  • Bernardi, Anna
  • Fieschi, Franck
DC-SIGN (CD209) and L-SIGN (CD209L) are two C-type lectin receptors (CLRs) that facilitate SARS-CoV-2 infections as viral co-receptors. SARS-CoV-2 manipulates both DC-SIGN and L-SIGN for enhanced infection, leading to interest in developing receptor antagonists. Despite their structural similarity (82% sequence identity), they function differently. DC-SIGN, found in dendritic cells, shapes the immune response by recognizing pathogen-associated carbohydrate patterns. In contrast, L-SIGN, expressed in airway epithelial endothelial cells, is not directly involved in immunity. COVID-19's primary threat is the hyperactivation of the immune system, potentially reinforced if DC-SIGN engages with exogenous ligands. Therefore, L-SIGN, co-localized with ACE2-expressing cells in the respiratory tract, is a more suitable target for anti-adhesion therapy. However, designing a selective ligand for L-SIGN is challenging due to the high sequence identity of the Carbohydrate Recognition Domains (CRDs) of the two lectins. We here present Man84, a mannose ring modified with a methylene guanidine triazole at position 2. It binds L-SIGN with a KD of 12.7μM ± 1 μM (ITC) and is the first known L-SIGN selective ligand, showing 50-fold selectivity over DC-SIGN (SPR). The X-ray structure of the L-SIGN CRD/Man84 complex reveals the guanidinium group's role in achieving steric and electrostatic complementarity with L-SIGN. This allows us to trace the source of selectivity to a single amino acid difference between the two CRDs. NMR analysis confirms the binding mode in solution, highlighting Man84's conformational selection upon complex formation. Dimeric versions of Man84 achieve additional selectivity and avidity in the low nanomolar range. These compounds selectively inhibit L-SIGN dependent trans-infection by SARS-CoV-2 and Ebola virus. Man84 and its dimeric constructs display the best affinity and avidity reported to date for low-valency glycomimetics targeting CLRs. They are promising tools for competing with SARS-CoV-2 anchoring in the respiratory tract and have potential for other medical applications.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glycan-Silica Nanoparticles as Effective Inhibitors for Blocking Virus Infection

  • Pérez, Carmen M.
  • Lasala, Fátima
  • Rodríguez, Laura
  • Delgado, Rafael
  • Rojo, Francisco Javier
  • Ramos-Soriano, Javier
Chemicals and CAS Registry Numbers concanavalin A 11028-71-0 silicon dioxide 10279-57-9, 14464-46-1, 14808-60-7, 15468-32-3, 60676-86-0, 7631-86-9 Antiviral Agents Cell Adhesion Molecules Concanavalin A DC-specific ICAM-3 grabbing nonintegrin Lectins, C-Type Polysaccharides Receptors, Cell Surface Silicon Dioxide, Small solid silica nanoparticles (SiNPs) have been used for multivalent carbohydrate presentation in DC-/L-SIGN-mediated viral infection models. Glycosylated SiNPs (glycoSiNPs) were fully characterized by different experimental techniques, including NMR, DLS, TGA, FTIR, and XPS, which confirmed their chemical structures. As a proof-of-concept, the capacity of glycoSiNPs to interact with Concanavalin A (ConA), a model lectin, using DLS binding experiments and UV-vis turbidimetry assays was analyzed. Their antiviral activity was assessed in a cellular assay using an artificial Ebola virus, demonstrating the potent inhibition of DC-SIGN-mediated infection. Notably, glycoSiNPs functionalized with a trivalent Manα1,2Man glycodendron exhibited the strongest inhibitory activity, with an IC50 of 135 ng/mL and a 170-fold lower efficiency in blocking L-SIGN-mediated viral infection. These findings suggest that glycoSiNPs present a promising approach for developing antiviral agents that selectively target the DC-SIGN pathway over the L-SIGN one., This research was funded by grant from MCIN/AEI/10.13039/501100011033 (PID2020-118403GB-I00) cofunded by the European Regional Development Fund (ERDF) “A way of making Europe” and grants CIBERINFEC and FIS PI2100989 from Instituto de Salud Carlos III and Project Ebola PREP-TBOX. HORIZON-JU-GH-EDCTP3-2023-01ID 101145709 from the European Commission to R.D. Comunidad de Madrid (CM) through project PR27/21-005 is also acknowledged. J.R.-S. acknowledges the support of Ramón y Cajal (RYC2022-037742-I) and C.P.-A. thanks MICIU for an FPI scholarship (PRE2021-097496) funded by MCIN/AEI/10.1339/501100011033 and by “ESF+.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From diarylsulfides to diarylamines: new Ebola virus entry inhibitors with improved metabolic stability

  • Morales-Tenorio, Marcos
  • Lasala, Fátima
  • García-Rubia, Alfonso
  • Aledavood, Elnaz
  • Heung, Michelle
  • Olal, Catherine
  • Escudero-Pérez, Beatriz
  • Oquist, Paola
  • Canales, Ángeles
  • Alonso Martí, Covadonga
  • Martínez Gil, Ana
  • Muñoz-Fontela, César
  • Delgado, Rafael
  • Gil, Carmen
15 p.-7 fig.-4 tab.-1 graph. abst., The persistence of current outbreaks of Ebola virus (EBOV) disease and challenges in the production and administration of approved vaccines and treatments highlight the continuous exploration of new therapeutic alternatives. In this context, this work focuses on optimizing diarylsulfide hits previously identified as EBOV entry inhibitors. Structural modifications resulted in diarylamine derivatives, with confirmed antiviral activity against replicative EBOV and significantly improved metabolic stability compared to diarylsulfides. Using different techniques, the EBOV glycoprotein (EBOV-GP) was identified as the target of these compounds. Residue Y517GP2 is critical for biological activity, while T519GP2, E100GP1, and D522GP2 also contribute to ligand binding. Furthermore, the binding of the derivatives to EBOV-GP has been shown to destabilize the complex with the virus receptor NPC1. In short, a new family of diarylsulfides and diarylamines with antiviral activity against EBOV has been developed, and their mechanism of action has been deciphered, paving the way for future pharmaceutical development., The project leading to these results has received funding from “la Caixa” Foundation under the project code LCF/PR/HR19/52160012. This research was partially supported through ERA-NET-2021-862605 and cofounded by MICIU/AEI/10.13039/501100011033 and FEDER/UE (Grants PCI2021-121939 (C.A.), PID2021-122825OB (C.A.), PID2023-151109OB-I00 (A.C.) and PID2021-122223OB-I00 (C.G.)), Instituto de Salud Carlos III (CIBERINFEC, CIBERNED and FIS PI2100989), and the European Commission Project e-FabRIC: ID: 101137157, HORIZON-HLTH-2023-DISEASE-03-04 and Project Ebola PREP-TBOX, ID 101145709, and HORIZON-JU-GH-EDCTP3-2023-01 to RD. This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI+ Salud Global). M.M.-T. holds a predoctoral FPU grant (FPU18/03493) from MICINN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oral immunization with filovirus-like particles partially protects IFNAR-/- mice against lethal ebola virus challenge

  • Escudero-Pérez, Beatriz
  • Lasala, Fátima
  • Luczkowiak, Joanna
  • Labiod, Nuria
  • Rivas, Gonzalo
  • Morgado, Hugo
  • Casasnovas, José María
  • Nave, Julia
  • Wurr, Stephanie
  • García-Bernalt Diego, Juan
  • Muñoz-Fontela, César
  • Delgado, Rafael
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-026-44944-0, Ebola virus (EBOV), a member of the Filoviridae family, is responsible for severe hemorrhagic fever outbreaks with high case fatality rates in humans. Although injectable vaccines have shown efficacy, their deployment remains challenging in outbreak settings due to cold-chain requirements and the need for trained personnel. Oral vaccination offers an attractive alternative, combining ease of administration with the potential to induce both mucosal and systemic immunity. In this study, we evaluated the immunogenicity and protective efficacy of an orally-administered Ebola virus filovirus-like particle (EBOV-VLP) vaccine in type I interferon receptor-deficient (IFNAR-/-) mice. Mice received one or three oral doses of EBOV-VLP prior to intranasal challenge with a lethal dose of EBOV. Our data demonstrate that oral immunization with EBOV-VLP elicits specific humoral immune responses and confers partial protection against lethal EBOV infection. These findings support further exploration of VLP-based oral vaccines as a potential component of EBOV disease preparedness strategies., Supported by grants to RD from the European Comission: Ebola-Prep-TBox. HORIZON-JU-GH-EDCTP3-2023-01, ID 101145709, Comunidad de Madrid: Retar-a-COVID S2022/BMD-7274, and Instituto de Salud Carlos III: CIBERINFEC. GR and JGDB are supported by Instituto de Salud Carlos III (Rio Hortega Grants CM20/00205 and Sara Borrell Grant CD23/00174 respectively). Partially supported by grant TTU 01.702 from the German Center of Infection (DZIF) to CMF., Peer reviewed, Modelo experimental alternativo-NAM, in vitro - Tipos celulares
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oral immunization with virus-like particles elicits Ebola virus-specific humoral and cellular immune responses in mice

  • Lasala, Fátima
  • Luczkowiak, Joanna
  • Labiod, Nuria
  • Rivas, Gonzalo
  • Arce, Octavio
  • Alonso, Marina
  • Kremer, Leonor
  • Casasnovas, José María
  • Olal, Catherine
  • Heung, Michelle
  • Escudero-Pérez, Beatriz
  • García-Bernalt Diego, Juan
  • Muñoz-Fontela, César
  • Delgado, Rafael
Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2026.128764, Ebola virus (EBOV) poses a significant public health threat due to its high case fatality rates and proved human-to-human transmission. While licensed vaccines exist for EBOV, their intramuscular administration presents some logistical challenges in outbreak settings. Oral vaccines offer advantages in accessibility, compliance, and scalability but have not been explored for EBOV., Supported by grants to RD from the European Comission: Ebola-Prep-TBox. HORIZON-JU-GH-EDCTP3-2023-01. ID 101145709, Comunidad de Madrid: Retar-a-COVID S2022/BMD-7274, and Instituto de Salud Carlos III: DTS15/00171, FIS2100989 and CIBERINFEC. GR, OA and JGDB are supported by Instituto de Salud Carlos III (Rio Hortega Grants CM20/00205and CM23/00257 and Sara Borrell Grant CD23/00174 respectively)., Peer reviewed, Modelo experimental alternativo-NAM, in vitro - Tipos celulares